Metronomic capecitabine inhibits liver transplant rejection in rats by triggering recipients’ T cell ferroptosis

Figure 3 Metronomic capecitabine decreased the infiltration of CD3⁺ T cells in peripheral blood, liver allografts, and spleen. A: The percentage of CD3⁺ T cells among lymphocytes in the peripheral blood at postoperative day 7; B: The number of CD3⁺ T cells in the peripheral blood at postoperative day 7; C and D: Grafted liver (C) and spleen (D) sections were stained for CD3. The samples from each group were collected on postoperative day 7. The arrows show positive staining (50 × and 200 ×). Quantification of the proportion of CD3⁺ positive area within a given section (%). Statistical analysis was done by unpaired t-test, n = 6. Data are shown as mean ± SD; ^aP < 0.05 vs the control group, ^cP < 0.001 vs the control group. CON: Untreated control groups, rats received 0.9% normal saline for 7 d; MET: Metronomic capecitabine (CAP)-treated groups, rats received metronomic CAP (100 mg/kg/d) treated for 7 d.